Taurine: The Amino Acid That Declines With Age

Evidence Review

Taurine and Aging (Singh et al., 2023)

The most important recent study on taurine is Singh P et al. (2023), published in Science [PMID 37289866]. This multi-species investigation measured circulating taurine concentrations across worms (C. elegans), mice, rhesus monkeys, and approximately 12,000 European adults aged 60 and over. Key findings:

• Taurine concentrations decline ~80% from youth to old age in humans
• In mice, taurine supplementation extended median lifespan by 10–12% in middle-aged animals
• Treated mice showed reduced body fat, increased bone density, greater muscle endurance, lower fasting glucose, reduced depression-like behavior, and improved immune function
• In rhesus monkeys given taurine for 6 months, there were measurable reductions in fasting blood glucose, liver damage markers, and increased bone density
• In the human observational cohort, higher taurine levels were associated with lower rates of obesity, type 2 diabetes, hypertension, and inflammatory markers

Mechanistically, taurine reduced cellular senescence, protected against telomere shortening, suppressed mitochondrial dysfunction, decreased DNA damage markers, and attenuated "inflammaging" (the chronic, low-grade inflammation associated with aging). The authors characterized taurine deficiency as a likely driver — though not the sole cause — of mammalian aging. It's worth noting that this is a significant claim, and the longevity findings come primarily from animal models; controlled longevity trials in humans are not yet feasible.

Cardiovascular Meta-Analysis (2024)

A systematic review and meta-analysis published in Nutrition Journal [PMID 39148075] pooled data from randomized controlled trials examining taurine's effects on hemodynamic parameters. The analysis found:

• Heart rate reduction: WMD = −3.58 bpm (95% CI: −6.04 to −1.11; p = 0.004)
• Systolic blood pressure: WMD = −4.0 mmHg (95% CI: −7.29 to −0.71; p = 0.017)
• Diastolic blood pressure: WMD = −1.4 mmHg (95% CI: −2.48 to −0.39; p = 0.007)
• Left ventricular ejection fraction: WMD = +4.98% (95% CI: +1.56 to +8.41; p = 0.004)

No significant adverse effects were reported relative to placebo. The effects were most pronounced in patients with pre-existing heart failure or hypertension, though healthy individuals also showed benefit.

Anti-Inflammatory Mechanisms (Qaradakhi et al., 2020)

Qaradakhi and colleagues published a detailed mechanistic review in Nutrients [PMID 32957558] exploring how taurine reduces cardiovascular inflammation. Taurine inhibits the production of angiotensin II (a potent vasoconstrictor), increases ACE2 expression (protective arm of the renin-angiotensin system), and suppresses NF-κB signaling — a central pathway in the inflammatory cascade. Taurine also reduces LDL oxidation and foam cell formation, two critical steps in atherosclerotic plaque development. The authors highlighted taurine's potential as an adjunct therapy for cardiovascular disease, noting its excellent safety margin distinguishes it from pharmaceutical options.

Heart Failure Clinical Trial (Ahmadian et al., 2017)

A double-blind randomized trial [PMID 28118062] assigned 16 heart failure patients to taurine (500 mg three times daily) or placebo for two weeks. The taurine group showed significantly improved:

• Exercise tolerance (6-minute walk test distance)
• Myocardial oxygen consumption (reduced oxygen demand at equivalent workloads)
• QT interval normalization and T-wave amplitude on ECG

The sample size was small, limiting generalizability, but the effect sizes were meaningful and consistent with the mechanistic literature on taurine and cardiac function.

Exercise Performance Systematic Review (Kurtz et al., 2021)

Kurtz JA et al. in Frontiers in Physiology [PMID 34497536] systematically reviewed the dose-response relationship of taurine on both aerobic and strength exercise outcomes. Reviewing 10 controlled studies, they found that 1–3 g/day for 6–15 days, taken 1–3 hours before activity, improved time to exhaustion, strength output, delayed-onset muscle soreness, and reduced markers of oxidative stress (creatine kinase, lactate dehydrogenase). The evidence was more consistent for aerobic than anaerobic performance, and the review noted that timing and duration of supplementation appear to matter — single acute doses showed smaller effects than multi-day protocols.

Neuroprotection (Rafiee et al., 2022)

A review in Nutrients [PMID 35334949] examined taurine's role in protecting the brain in the context of metabolic dysfunction. Taurine modulates calcium homeostasis in neurons, activates inhibitory GABA-A and glycine receptors, and reduces neuroinflammation via microglial suppression. Animal studies show taurine increases hippocampal neurogenesis, protecting the memory center of the brain from aging-related decline. In models of Parkinson's disease, taurine reduced dopaminergic neuron loss and improved behavioral outcomes. The review noted that brain taurine levels are particularly vulnerable to metabolic stress from obesity and high blood glucose — conditions where supplementation may provide the greatest benefit.

Strength of Evidence

The cardiovascular evidence in heart failure patients is reasonably strong (multiple RCTs with consistent effects). The aging/longevity data is compelling but primarily from animal models — the human epidemiological association is suggestive, not causal. Exercise performance evidence is moderate quality (heterogeneous protocols, small trials). The neuroprotective data is largely preclinical. Overall, taurine has an unusually strong safety record, which makes it a low-risk supplement for those seeking cardiovascular, metabolic, or performance support — particularly for vegans, vegetarians, and those over 40 whose natural levels are declining.